BACKGROUND: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids does not appear to be as effective as similar treatment of asthma. It seems that only certain subgroups of patients with COPD benefit from steroid treatment. A study was undertaken to examine whether inhaled fluticasone propionate (FP) had an effect on lung function and on indices of inflammation in a subgroup of COPD patients with bronchial hyperresponsiveness (BHR). METHODS:Twenty three patients with COPD were studied. Patients had to be persistent current smokers between 40 and 70 years of age. Non-specific BHR was defined as a PC(20) for histamine of <or=8 mg/ml. Patients received either 2 x 500 microg FP or placebo for 6 months. Expiratory volumes were measured at monthly visits, BHR was determined at the start of the study and after 3 and 6 months, and bronchial biopsy specimens were taken at the start and after 6 months of treatment. Biopsy specimens from asymptomatic smokers served as controls. RESULTS: In contrast to asthma, indices of BHR were not significantly influenced by treatment with FP. Forced expiratory volume in 1 second (FEV(1)) showed a steep decline in the placebo group but remained stable in patients treated with FP. FEV(1)/FVC, and maximal expiratory flows at 50% and 25% FVC (MEF(50), MEF(25)) were significantly increased in the FP treated patients compared with the placebo group. Biopsy specimens were analysed for the presence of CD3+, CD4+, CD8+, MBP+, CD15+, CD68+, CD1a, and tryptase cells. FP treatment resulted in marginal reductions in these indices of inflammation. CONCLUSION: In patients with COPD and BHR, FP has a positive effect on indices of lung function compared with placebo. Bronchial inflammation analysed in bronchial biopsy specimens is only marginally reduced.
RCT Entities:
BACKGROUND: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids does not appear to be as effective as similar treatment of asthma. It seems that only certain subgroups of patients with COPD benefit from steroid treatment. A study was undertaken to examine whether inhaled fluticasone propionate (FP) had an effect on lung function and on indices of inflammation in a subgroup of COPDpatients with bronchial hyperresponsiveness (BHR). METHODS: Twenty three patients with COPD were studied. Patients had to be persistent current smokers between 40 and 70 years of age. Non-specific BHR was defined as a PC(20) for histamine of <or=8 mg/ml. Patients received either 2 x 500 microg FP or placebo for 6 months. Expiratory volumes were measured at monthly visits, BHR was determined at the start of the study and after 3 and 6 months, and bronchial biopsy specimens were taken at the start and after 6 months of treatment. Biopsy specimens from asymptomatic smokers served as controls. RESULTS: In contrast to asthma, indices of BHR were not significantly influenced by treatment with FP. Forced expiratory volume in 1 second (FEV(1)) showed a steep decline in the placebo group but remained stable in patients treated with FP. FEV(1)/FVC, and maximal expiratory flows at 50% and 25% FVC (MEF(50), MEF(25)) were significantly increased in the FP treated patients compared with the placebo group. Biopsy specimens were analysed for the presence of CD3+, CD4+, CD8+, MBP+, CD15+, CD68+, CD1a, and tryptase cells. FP treatment resulted in marginal reductions in these indices of inflammation. CONCLUSION: In patients with COPD and BHR, FP has a positive effect on indices of lung function compared with placebo. Bronchial inflammation analysed in bronchial biopsy specimens is only marginally reduced.
Authors: P M van Grunsven; C P van Schayck; J P Derenne; H A Kerstjens; T E Renkema; D S Postma; T Similowski; R P Akkermans; P C Pasker-de Jong; P N Dekhuijzen; C L van Herwaarden; C van Weel Journal: Thorax Date: 1999-01 Impact factor: 9.139
Authors: D E Niewoehner; M L Erbland; R H Deupree; D Collins; N J Gross; R W Light; P Anderson; N A Morgan Journal: N Engl J Med Date: 1999-06-24 Impact factor: 91.245
Authors: R A Pauwels; C G Löfdahl; L A Laitinen; J P Schouten; D S Postma; N B Pride; S V Ohlsson Journal: N Engl J Med Date: 1999-06-24 Impact factor: 91.245
Authors: Adriana L da Silva; Sabrina V Martini; Soraia C Abreu; Cynthia dos S Samary; Bruno L Diaz; Sandra Fernezlian; Vanessa Karen de Sá; Vera Luiza Capelozzi; Nicholas J Boylan; Rodolfo Gustavo Goya; Jung Soo Suk; Patricia R M Rocco; Justin Hanes; Marcelo M Morales Journal: J Control Release Date: 2014-02-17 Impact factor: 9.776
Authors: Geert R Van Pottelberge; Ken R Bracke; Ingel K Demedts; Kim De Rijck; Susanne M Reinartz; Cornelis M van Drunen; Geert M Verleden; Frank E Vermassen; Guy F Joos; Guy G Brusselle Journal: Respir Res Date: 2010-03-22
Authors: Jiska B Snoeck-Stroband; Therese S Lapperre; Peter J Sterk; Pieter S Hiemstra; Henk A Thiadens; H Marike Boezen; Nick H T Ten Hacken; Huib A M Kerstjens; Dirkje S Postma; Wim Timens; Jacob K Sont Journal: PLoS One Date: 2015-12-10 Impact factor: 3.240